Introduction Multiple sclerosis (MS) has significant financial consequences for healthcare systems, individual patients and households, and the wider society. This study examines the distribution of MS costs and resource utilisation across cost categories and from various perspectives, as MS disability increases. Methods Two hundred and fourteen patients with MS were recruited from a specialist MS outpatient clinic in Ireland and included in an interview-based study on MS-related healthcare resource consumption and costs. Patients were grouped into three categories based on disability: mild [Expanded Disability Status Scale (EDSS) score 0-3.5, n = 114], moderate (EDSS 4.0-6.5, n = 72) and severe (EDSS 7.0-9.5, n = 27). The mean annual direct and indirect costs (in year 2012 values) were estimated using non-parametric bootstrapping. Results Participants were 66.4 % female, with a mean age of 47.6 years and a mean EDSS score of 3.6. The majority had relapsing-remitting MS (RRMS) (53 %). The mean annual direct (indirect) costs per person were €10,249 (€9,447), €13,045 (€31,806) and €56,528 (€39,440) in mild, moderate and severe MS, respectively. Direct costs are driven by the cost of diseasemodifying therapies and professional home help in mild and severe MS, respectively. Between 74 % (severe MS) and 96 % (mild MS) of all direct costs are borne by the healthcare payer, the remainder being incurred by patients, their families or other non-healthcare organisations.
Key Points for Decision Makers
Multiple sclerosis (MS) is associated with high levels of healthcare resource consumption and costs, which increase with disability
The economic impact of increasing disability is particularly apparent in the shift in direct costs between moderate and severe disability. As MS disability increases, the overall management approach changes from acute inpatient and outpatient intervention to more supportive homebased management strategies, shifting the burden of direct costs from medical to non-medical resources Productivity losses are similar in moderate and severe disease, indicating that the shift away from employment is largely complete before disability reaches the severe stage There is potential to significantly reduce the economic burden of MS through interventions that prevent progression from mild/moderate to severe disability, support independent living at home and maintain labour force participation
Introduction
Multiple sclerosis (MS) is a chronic, disabling disease characterised by inflammation and multifocal demyelination in the central nervous system. The majority of patients experience an initial relapsing-remitting (RR) disease course, typically characterised by episodic loss of neurological function, followed by complete or partial recovery. This RR phase may last approximately 10-20 years, but the majority of people with initial RRMS will develop secondary progressive MS (SPMS), characterised by progressive, permanent disability, at some stage [1] . A smaller subset of patients develop primary progressive MS (PPMS), for whom progressive neurological disability occurs from onset [2] . MS is twice as common in women as in men. The estimated median global prevalence of MS is 30 people per 100,000, although significant geographical variation exists [3] . The prevalence in Ireland is between 180 and 290/100,000 [4] .
The condition is associated with significant economic and health-related quality-of-life (HRQoL) burden. An unpredictable disease course can include clinical features such as pain and loss of sensation, fatigue, impaired muscle control, balance and postural problems, visual loss, cognitive impairments, and bowel and bladder disturbance. HRQoL has been shown to diminish in line with increasing physical disability [5] . Healthcare resource utilisation in MS has significant financial consequences for the healthcare system, patients and their families. During the RR phase of the disease, pharmacological and other interventions are used to treat relapses, manage symptoms, and attempt to delay disease progression. As the disease progresses, symptom management predominates, with the aim of maintaining independence and functioning both at work and at home. This often requires a complex multidisciplinary approach including inpatient, ambulatory, and home-based rehabilitation interventions under medical supervision [6] . The average age at onset of MS is approximately 30 years [7] . As the leading cause of nontraumatic neurological disability in young adults, MS imposes significant additional indirect cost burdens on society. Neurological symptoms of varying severity can result in functional limitations that can severely impact patients' physical activity, employment capabilities and opportunities. These limitations can result in prolonged absences from work, early retirement from the work force and significant care requirements from both professional caregivers and from family and friends.
Previous studies have invariably found costs to increase as disability levels increase [8] [9] [10] . However, significant variation in cost estimates exist between studies, reflecting differences in study methodologies and differences in how healthcare is organised and delivered in different countries. Inconsistencies in the classification of direct and indirect costs, and in the definition of the ''payer'', have also been identified [8, [10] [11] [12] [13] . The MS therapeutic landscape is undergoing significant change. The number of patients treated with high-cost disease-modifying therapies (DMTs) is increasing in response to clinical trials supporting their use early in the disease process [14] [15] [16] [17] . The number of available DMTs is also expanding rapidly. The aim of this cost-of-illness study was to investigate the economic consequences of increasing MS disability from the perspective of the Irish healthcare payer, patients and society in general. Both direct and indirect costs were calculated in order to assess the total economic burden of MS.
Methods

Patients and Data Collection
Using a prevalence-based approach, the annual costs of MS were estimated for a cohort of patients with a confirmed diagnosis of MS attending a specialist MS outpatient clinic at St. Vincent's University Hospital, Dublin, from September 2011 to February 2012. Details of study recruitment and inclusion criteria have been reported previously [5] . Following neurological consultation, patients were guided through a structured interview using a standardised questionnaire comprising questions on sociodemographic details and the history of their MS diagnosis and symptoms. The HRQoL instrument, the five-level EQ-5D (EQ-5D-5L), was also self-completed by all patients, the details and results of which are reported elsewhere [5] . Data were collected on the utilisation of medical and non-medical resources specifically attributable to MS. The questionnaire was based on the Client Service Receipt Inventory (CSRI), and adapted to the setting of the study. The CSRI is a research instrument extensively applied in psychiatry for the collection of information on costs and has been widely used in resource-use measurement studies, including those for MS [10, 18] . The length of the recall period for resource use varied depending on the expected frequency of resource use, e.g. 12 months for inpatient admissions, 6 months for outpatient and primary healthcare visits, laboratory and radiological investigations, and 1 month for medication and 1 week for home help. For resources such as mobility and other living aids (e.g. crutch, wheelchair, utensils, etc.) and major investments such as home modifications, the full duration of the disease was used for recall [19] . Costs are classified as direct medical, direct nonmedical and indirect. Direct medical costs included inpatient hospital admissions, rehabilitation, nursing home care, outpatient, primary healthcare and respite, laboratory, radiological and other investigations and medication. Direct non-medical costs included mobility and other living aids, major investments and home adaptations and professional help in the home. Indirect costs included lost productivity due to absenteeism from work, early retirement and informal care from family and friends. In the Irish healthcare system, all residents are entitled to free or subsidised public hospital care and everyone with MS is entitled to free MS-related prescription medication, medical and surgical appliances. The national Health Service Executive (HSE, the ''healthcare payer'') provides meanstested financial support to people who need long-term nursing home care. In the absence of data on the breakdown of healthcare payer/patient payments from patients in this study, we have made the assumption that long-term care is funded by the healthcare payer. Primary care entitlements are means-tested, with *40 % of the population entitled to free general practitioner care. A proportion of direct expenditure is therefore expected to be borne by patients, their families or other organisations. 
Unit Costs
Nationally applicable unit costs were applied to each resource component. The sources of unit costs are outlined in Table 1 . In the absence of standard unit costs, the cost of mobility/living aids and adaptations were based on patient estimates and publicly available price lists. These costs were annualised assuming a useful life of 5 years (mobility/living aids) or 10 years (major adaptations), using the national discount rate of 4.0 % per annum [20] . Where necessary, unit costs were inflated to 2012 values, using the consumer price index for health [21] . Productivity losses associated with reductions in working hours or sick leave and permanent withdrawal from the work force due to MS were based on national gender-stratified average gross hourly and annual earnings, respectively. This ''human capital'' approach to valuing productivity losses assumes that labour earnings reflect productive capacity. In a similar way, informal care was valued, using the opportunity cost approach, as earnings foregone as a result of time spent caregiving (up to a maximum of 40 h per week), using the national gross mean hourly wage in Ireland. This bottomup approach to cost estimation enabled extrapolation of annual costs to the general population.
Analysis
Direct medical, direct non-medical and indirect costs are presented from the societal perspective (i.e. regardless of who pays). Direct costs are further categorised by payer, i.e. healthcare payer, patient or other non-healthcare payer organisation (costs borne by patients, their families, nonhealthcare payer state agencies, charitable organisations, etc.). Disability was quantified using the Expanded Disability Status Scale (EDSS) [22] . The EDSS quantifies disability in a number of functional systems on a scale from 0 (normal neurological examination) to 10 (death from MS). Above EDSS 6.0, disability is largely dependent on walking function, and a score of 8.0 marks the loss of ambulation/wheelchair dependence. Patients were stratified on the basis of the severity of disability into three groups based on their EDSS score: mild (EDSS 0-3.5), moderate (EDSS 4-6.5) and severe (EDSS 7-9.5). Costs were annualised under the assumption that resource use during the recall period was representative of other periods of similar duration throughout the year. Descriptive statistics are presented as means and standard deviation. Proportions are calculated for categorical variables. The 95 % confidence intervals (CIs) were estimated by non-parametric bootstrapping to account for the skewed nature of cost distributions (truncated at zero and comprising relatively small numbers of patients with very high costs). Differences in the demographics and the costs between groups stratified by EDSS or disease type (RRMS, SPMS or PPMS) were compared by ANOVA and Kruskal-Wallis test, for parametric and non-parametric data, respectively. Statistical significance is based at the 0.05 level.
In multivariate analysis, we evaluated determinants of direct costs using a log transformation of the dependent variable. A backwards, stepwise procedure was used to reduce the model to include only significant covariates (p \ 0.05). A separate model was used to extrapolate costs from the study sample to the national population, assuming an overall population of 8,000 MS patients in Ireland [23] . Model covariates included age, gender, disease duration and MS subtype, using mean values from a 2007 crosssectional study including 632 patients from three regions of Ireland [4] . A national prescribing database was used to estimate the proportion of the MS population on DMTs [24] . To account for a substantial fraction of observations at zero-indirect cost, the indirect cost model was fitted as a mixture distribution, fitting the multiple regression to nonzero values only and using a logistic regression to estimate population costs proportionally (Electronic Supplementary Material).
All patients gave informed written consent regarding study participation, and ethical approval was granted by the Research and Ethics Committee of St. Vincent's University Hospital, Dublin, Ireland.
Results
Patients
A total of 214 patients were included in the study. The key demographic details are summarised in Table 2 . The mean (SD) EDSS score was 3.6 (2.6), with population peaks at EDSS 1 and EDSS 6. Some 53.5 % of patients had mild disease, 33.8 % had moderate disease and 12.7 % had severe disease. Patients with mild disease were younger compared with those with moderate or severe disease, had a shorter disease duration and were more likely to be employed (p \ 0.001).
Resource Utilisation
The proportion of patients using various resources is summarised in Table 3 . A total of 15.4 % of patients were hospitalised during the previous year [mean (SD) number of admissions per patient 1.3 (0.6), duration 1-167 days]. A DMT was prescribed for 61.4 and 29.6 % of patients with mild and moderate MS, respectively. A total of 92 % of those on a DMT were on a first-line agent (interferonbeta or glatiramer acetate). Regular help at home (from paid professionals or family and friends) was received by 9.6, 54.2 and 92.9 % of those with mild, moderate and severe MS, respectively. Significantly more patients with mild MS were in paid employment compared with patients with moderate or severe MS (54.4 vs. 23.2 %, p \ 0.05). MS-related sick leave or a reduction in working hours was taken by 32.6 % of those in paid employment [mean (SD) reduction in working days per week 0.89 (1.0)]. The majority of patients with moderate or severe disability were retired due to MS-related ill health (52.8 and 59.6 %, respectively). The mean (SD) age at retirement was 44.3 (10.7) years.
Healthcare Costs
The findings for annual direct medical, direct non-medical and indirect costs according to disease severity are summarised in Table 4 . For most of the cost categories, the costs increased in line with increasing disease severity/ disability. The notable exceptions to this were the cost of medication and investigations, for which costs were highest in those with mild disease. DMTs accounted for 76.1 and 29. 6 % of direct costs in mild and moderate MS, respectively. Excluding DMTs, the direct annual cost of moderate MS is significantly higher than that of mild MS (€2,454 vs. €8,133 p \ 0.05). Patients with severe disease had significantly higher costs than those with mild or moderate disease (p \ 0.05).
In contrast to mild and moderate MS, the direct nonmedical costs exceeded direct costs in severe MS. The provision of nursing home care, rehabilitation and respite care accounted for the greatest proportion of direct medical costs in those with severe MS, while the cost of professional help at home was the greatest contributor to direct non-medical costs in that group.
Patients with RRMS had lower mean annual direct costs than patients with SPMS [€10,907 (95 % CI €9,402-€12,358) vs. €26,505 (95 % CI €19,720-€34,061)] (p \ 0.05) (Fig. 1) . The mean annual cost was higher among RRMS patients with a recent relapse than among those without, but this difference was not statistically significant [mean (95 % CI) €3,228 (-€221 to €6,884), p = 0.18].
The distribution of costs among the various payers is shown in Fig. 2 . Between 74 and 96 % of direct costs are borne by the healthcare payer in Ireland. The remaining costs are incurred by patients, families or non-healthcare payer organisations, 78.47 % of those costs relating to nonmedical resources such as living aids, home modifications and home help.
Indirect costs increased as MS disability increased (Table 4) . Productivity losses of absenteeism/early retirement accounted for the greatest proportion of indirect costs (70.1 %). Productivity losses are similar in moderate and severe disease, indicating that the shift away from employment is largely complete before disability reaches the severe stage. Direct costs exceed indirect costs in mild and severe MS, driven by DMT costs and professional home help, respectively. In contrast, indirect costs dominate direct costs in patients with moderate disability (€31,806 vs. €13,045) primarily because of early retirement from the work force.
Independent predictors of total direct costs include disability, EQ5D-5L HRQoL index, DMT, and long-term care (p \ 0.01). Extrapolating costs from the study sample to the general population of MS patients in Ireland, national annual direct and indirect costs are predicted to be €127.8 million and €149.6 million, respectively.
Discussion
This study provides insights into the distribution of costs and resource utilisation across cost categories, from various perspectives, as disability increases and across the different MS subtypes. MS severity was an independent predictor of direct costs, highlighting the importance of delaying disability progression as an economic as well as clinical priority. The economic impact of increasing disability from the healthcare payer's perspective is particularly apparent in the shift in direct costs between moderate and severe disability. Mean annual direct costs increased more than fourfold from €12,822 to €55,960 per person with moderate and severe disease, respectively, driven by the excess cost of episodic/permanent institutional care and the provision of professional care in the home. As expected, the costs of DMT dominate in early MS, accounting for approximately 75 % of total direct costs in mild MS and RRMS. As a result, direct medical costs in mild MS exceed those in moderate MS, whereas direct non-medical costs increase in line with increasing disability. DMT utilisation falls significantly in moderate, severe and progressive disease types in line with guidelines suggesting discontinuation following the development of nonrelapsing SPMS with loss of ability to ambulate (EDSS C7.0) [25, 26] . In these subgroups, there is a shift in emphasis, away from expensive immunomodulator treatment, to symptomatic pharmacological treatments. As MS disability increases, the overall management approach changes from acute inpatient and outpatient intervention to more supportive home-based management strategies, longterm multidisciplinary management and rehabilitation. Direct costs in severe MS were dominated by the cost of providing care either in long-term care facilities or professional care at home.
Indirect costs exceed direct costs in moderate MS in contrast with mild and severe subgroups, where direct costs dominate, driven by DMT and professional home help, respectively. The level of early retirement among patients with moderate or severe MS was similar, indicating that the shift away from employment is largely complete before disability reaches the severe stage.
Both the financial and HRQoL impact on patients with MS can be significant. Patients' out-of-pocket costs have typically not been reported in other cost-of-MS studies. The majority of direct costs in our study are borne by the healthcare payer in Ireland. However, out-of-pocket spending at the individual patient level on non-medical resources and the contribution of non-healthcare payer organisations can be significant and were found to be particularly so in severe disease. The detrimental impact of increasing disability on the HRQoL of our cohort has been reported previously, and was further evaluated here with respect to patients' HRQoL utility at mild, moderate and severe stages of the disease [5] .
Two large European studies investigated the economic burden of MS across a number of countries in 2006 (Kobelt et al. [8, 11] ) and 2012/2013 (TRIBUNE study) [8, 11] . Cross-study comparisons must take into account the differential categorisation of informal care costs. In our study, indirect costs refer to all productivity losses, including those of the informal caregiver [27] . Informal care was categorised as a direct cost in both the Kobelt et al. and TRIBUNE studies. Excluding informal care from the direct costs of these studies, the mean annual direct cost per patient in our study (€17,103) is consistent with those reported by Kobelt et al. (€13,822-€30,721 in nine Table 4 Resource utilisation and mean annual direct and indirect costs by disease type European countries) and in the TRIBUNE study (€12,819-€24,578 in five European countries) (all costs inflated to € 2012).
In keeping with our study methodology, the TRIBUNE study also reported costs stratified by disease severity [8] . Direct medical costs in severe MS were higher than reported in TRIBUNE, most likely because of the inclusion of patients in long-term nursing home care, a group which have not been represented in most other studies. The costs of mild and moderate MS in our study are low compared with those reported in TRIBUNE, primarily because of the high level of DMT utilisation in the TRIBUNE sample. DMT utilisation in the total TRIBUNE population was very high, accounting for 43-94 % of direct costs in moderate MS, compared with 30 % of direct costs in moderate MS in our study. Eighty-eight per cent of those with moderate MS in our study had progressive disease. The efficacy of DMT in the setting of progressive disease is unproven, and discontinuation of DMT in these circumstances has been advocated [25, 26] . DMT utilisation has increased over the last decade in light of clinical trials reporting evidence of benefit when used early in the disease course [28] . Substantial investment in DMT in the early stages of MS aims to prevent or delay progression to advanced disease, thereby avoiding the cost associated with severe disability. DMTs have proven efficacy in reducing short-term disability progression in the setting of RCTs of 1-2 years duration. Despite advances in therapies, there is little evidence on the long-term efficacy of DMTs on reducing disability progression and conflicting results have been reported for the first-line DMTs interferon-beta and glatiramer acetate [29, 30] . Long-term studies are required to assess the benefits of DMT over time.
The mean cost of informal care is similar in our study to that reported elsewhere, despite lower levels of informal care provision in our study [8, 11, 31] . Unlike the TRI-BUNE study, we calculated productivity losses for time spent providing informal care, irrespective of whether the caregiver was in employment or otherwise. Kobelt et al. used the concept of loss of leisure time of family members, using the net disposable income after taxes, which yields lower unit costs. Average annual wages are higher in Ireland compared with many other OECD countries, which would be expected to lead to relatively higher indirect unit costs when using the human capital approach [32] . Productivity losses from absenteeism and early retirement are higher than in TRIBUNE (with the exception of the Netherlands study) and similar to those in the Kobelt et al. study, because of similar levels of early retirement in these studies. The study had a number of limitations. Our sample was recruited from a specialist MS outpatient clinic and as such is slightly biased towards those early in the disease course. However, the clinic also cares for patients with very severe disability, including those permanently resident in nursing homes, and this patient group is also represented in our sample. Stratification of patients and reporting of results according to mild, moderate and severe disease attempts to mitigate any overall sample bias.
Patients were recruited from just one centre and the extent to which our sample is representative of the general population of MS patients cannot be definitively assessed. The demographics of our sample are highly comparable with those of a cross-sectional epidemiological study that included 632 patients with MS from three different regions of Ireland [4] .
Self-report methods can introduce recall bias in retrospective resource-utilisation studies. Longer recall periods provide more information but are associated with recall error. Conversely, shorter recall periods have a greater risk of missing relevant information. There is no clear optimal recall period, and in keeping with other cost-of-illness studies, this study has used longer recall periods for large, infrequent events such as hospital admissions, and shorter periods for more frequent, recurrent events.
The assumption that nursing home care is funded by the healthcare payer (made in the absence of data on the proportion of privately financed long-term care) may have underestimated the patient/carer burden.
The opportunity cost approach employed in this study values caregiving at the wage the caregiver would earn if in paid employment, based on national mean annual earnings. We did not distinguish between carers who were in paid employment and those who were not. This approach may potentially lead to an overestimation of the actual productivity losses to society. However, a conservative approach to quantifying caregiving time was also taken, by placing a cap on caregiving hours in line with the average number of working hours per week.
Conclusion
MS is a high-cost therapeutic area, with significant economic implications for society as a whole, and for individual patients whose HRQoL is also adversely affected. Economic consequences are most associated with progression from mild or [5] . EQ-5D-5L five-level EQ-5D, HRQoL Health-Related Quality of Life, HSE Health Service Executive moderate to severe disease, loss of independence in the home and early withdrawal from the work force. It follows that interventions that aim to prevent or delay disease progression, support independent living at home and maintain work force participation have the potential to reduce overall costs associated with MS, while enhancing patient independence and HRQoL. Information on the total direct and indirect costs of MS provides the economic framework upon which questions of resource allocation and expenditure on such interventions can be based. Such questions require further information on the costs and benefits of possible health interventions in order to estimate efficiency and cost effectiveness.
